• HS, Covid-19 and Life

    In light of everything going on with COVID-19, the HS Foundation has teamed up with LearnSkin to provide guidance to HS physicians and patients about risks and management considerations in this challenging and unusual time.

    Read more

  • More News on Scenesse in Vitiligo

    Clinuvel just announced today that the FDA has agreed to discuss and implement the North American development program for SCENESSE (afamelanotide 16mg) for the pigment loss disorder vitiligo.

    Read more

  • New medicine for life-threatening peanut allergy

    Peanut allergy affects about 1 million children in the US and only 1 in 5 will outgrow this potentially life-threatening condition. Palforzia, a new medicine designed to lessen the overwhelming allergic reaction to peanuts was approved by the FDA on January 31, 2020. While this new therapy won’t enable peanut-allergic people to consume peanuts with abandon, it will significantly reduce the reaction, hopefully preventing hospitalization or worse.

    Read more

  • Scenesse for Vitiligo

    October 8th, 2019 marked a milestone event. Scenesse (afomelanotide) was approved by the FDA for use in an orphan disease called erythropoietic protoporphyria (EPP). This disease is marked by sensitivity to visible light resulting in skin cancers and significant skin damage.

    Read more

  • Moisturization: Not “once and done”!

    Moisturize means “make less dry”. Emollient means “having the quality of softening or soothing the skin”. Humectant means “retaining or preserving moisture”. You can see they all mean essentially the same thing, keeping the skin moist. Now that we have the terminology down, the solution is easy.

    Read more

FirstPrevious | Pages 1 2 [3] 4 5 6 7 8 of 11 | Next | Last

Love this Post? Spread the World